Evaluating oncogenic drivers in lung cancer patients at a cancer institute
Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D)
Centro di Riferimento Oncologico - Aviano · NCT06180005
This study is trying to find out how common certain gene changes are in people with non-small cell lung cancer to see if they can help guide better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Sex | All |
| Sponsor | Centro di Riferimento Oncologico - Aviano (other) |
| Locations | 1 site (Aviano, Pordenone) |
| Trial ID | NCT06180005 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the frequency of oncogene addiction in patients diagnosed with non-small cell lung cancer (NSCLC) at the Cancer Institute in Aviano. It focuses on identifying specific mutations such as EGFR, ALK, RET, KRAS, BRAF, Her2, ROS1, and MET that may serve as therapeutic targets. By analyzing these mutations, the study seeks to understand their prevalence and potential impact on treatment outcomes. The study will include patients who have their first visit or admission to the institute between September 2023 and September 2028.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with non-small cell lung cancer at any stage who are visiting the Cancer Institute for the first time.
Not a fit: Patients with tumors of uncertain lung origin will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for lung cancer patients by identifying targetable mutations.
How similar studies have performed: Previous studies have shown that identifying oncogenic driver mutations can significantly improve treatment outcomes, suggesting this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * First visit or first admission to CRO occurred in the period from September 2023 to September 2028 * Diagnosis of NSCLC any stage Exclusion Criteria: \- Diagnosis of tumor not of certain lung origin (uncertain origin)
Where this trial is running
Aviano, Pordenone
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (RECRUITING)
Study contacts
- Principal investigator: Alessandro Del Conte, MD — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Alessandro Del Conte, MD
- Email: alessandro.delconte@cro.it
- Phone: 0434 399464
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non Small Cell Lung Cancer